Edition:
United States

Adamis Pharmaceuticals Corp (ADMP.OQ)

ADMP.OQ on NASDAQ Stock Exchange Capital Market

4.35USD
21 May 2018
Change (% chg)

-- (--)
Prev Close
$4.35
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
96,748
52-wk High
$6.45
52-wk Low
$2.35

Chart for

About

Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M). The Company's... (more)

Overall

Beta: 0.32
Market Cap(Mil.): $156.93
Shares Outstanding(Mil.): 33.39
Dividend: --
Yield (%): --

Financials

  ADMP.OQ Industry Sector
P/E (TTM): -- 28.56 32.59
EPS (TTM): -0.59 -- --
ROI: -58.89 13.05 12.60
ROE: -66.18 14.79 14.49

BRIEF-Adamis Pharmaceuticals Updates Symjepi Commercialization Plans

* ADAMIS PHARMACEUTICALS UPDATES SYMJEPI COMMERCIALIZATION PLANS

Feb 23 2018

BRIEF-Adamis Pharmaceuticals Announces FDA Acceptance For Review For The  Supplemental New Drug Application

* ADAMIS PHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE FOR REVIEW FOR THE SUPPLEMENTAL NEW DRUG APPLICATION OF ITS LOW DOSE SYMJEPI PRODUCT CANDIDATE

Feb 12 2018

BRIEF-Adamis Pharmaceuticals Subsidiary Develops Compound To Manage Ulcers In Horses

* US COMPOUNDING, A SUBSIDIARY OF ADAMIS PHARMACEUTICALS, DEVELOPS A UNIQUE COMPOUND TO MANAGE ULCERS IN HORSES Source text for Eikon: Further company coverage:

Dec 06 2017

BRIEF-Adamis Pharmaceuticals Announces Submission Of Investigational New Drug (Ind) Application To The FDA

* ADAMIS PHARMACEUTICALS ANNOUNCES SUBMISSION OF INVESTIGATIONAL NEW DRUG (IND) APPLICATION TO THE FDA FOR NEW PRODUCT CANDIDATE FOR THE TREATMENT OF OPIOID OVERDOSE Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

Dec 04 2017

BRIEF-Adamis Pharma Submits Prior Approval Supplement To FDA For The Pediatric Version Of Symjepi

* ADAMIS PHARMACEUTICALS SUBMITS PRIOR APPROVAL SUPPLEMENT TO FDA FOR THE PEDIATRIC VERSION OF SYMJEPI

Nov 29 2017

Competitors

  Price Chg
GlaxoSmithKline plc (GSK.L) 1,509.80 +13.00

Earnings vs. Estimates